Drug intelligence / Profile preview

STAR0310

Development stage: Phase 1
Lead developer: Astria Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

STAR0310 is a monoclonal antibody antagonist targeting the OX40 receptor (tumor necrosis factor receptor superfamily member 4), currently in Phase 1 clinical development for the treatment of atopic dermatitis and potentially other inflammatory conditions such as hidradenitis suppurativa. Developed by Astria Therapeutics (acquired by BioCryst Pharmaceuticals), the biologic utilizes half-life extension technology designed to enable infrequent dosing every two to three months. It is engineered for high potency and a favorable safety profile, specifically characterized by low T-cell depletion via antibody-dependent cellular cytotoxicity (ADCC). Following BioCryst's acquisition of Astria in early 2026, the company announced plans to pursue strategic alternatives for the program.

Other names: ISB 830-X8ISB830-X8ISB-830-X8

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on STAR0310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STAR0310.

Explore the full profile